| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-09-15 | Domainex (UK) Auspherix (Australia) | antibiotic-resistant bacterial infections | collaboration |
Infectious diseases | Collaboration agreement | |
| 2015-09-15 | Aerie Pharmaceuticals (USA - CA) Ramot (Israel) | preclinical anti-beta amyloid small molecule product candidate | neuroprotection, dry age-related macular degeneration (dry AMD) | R&D licensing |
Ophtalmological diseases | Licensing agreement |
| 2015-09-15 | Kite Pharma (USA - CA) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2015-09-15 | PharmaMar (Spain) | establishment of a new subsidiary in the EU |
Cancer - Oncology | Establishment of a new subsidiary in the EU | ||
| 2015-09-15 | Pfenex (USA - CA) | nomination |
Nomination | |||
| 2015-09-15 | Celyad previously known as Cardio3 Bioscience (Belgium) | nomination |
Cardiovascular diseases - Regenerative medicine | Nomination | ||
| 2015-09-15 | Abivax (France) | nomination |
Infectious diseases | Nomination | ||
| 2015-09-15 | Merck KGaA (Germany) | nomination |
Nomination | |||
| 2015-09-15 | Curevac (Germany) | establishment of a new subsidiary in the US |
Infectious diseases | Establishment of a new subsidiary in the US | ||
| 2015-09-14 | Anthera Pharmaceuticals (USA - CA) Zenyaku Kogyo | blisibimod | lupus, IgA nephropathy | licensing |
Autoimmune diseases - Renal diseases | Termination of an agreement |
| 2015-09-14 | Kite Pharma (USA - CA) Netherlands Cancer Institute (NKI) (The Netherlands) | multiple T cell receptor (TCR) gene sequences | solid tumors | licensing collaboration |
Cancer - Oncology | Licensing agreement |
| 2015-09-11 | Medimmune (USA - global biologics arm of AstraZeneca (UK) Cancer Research UK (UK) Cancer Research Technology (CRT) (UK) | CRUK-MEDI Alliance Laboratory | opening of new premises - collaboration | Cancer - Oncology | Opening of new premises | |
| 2015-09-11 | Amgen (USA - CA) AstraZeneca (UK) | plant acquisition |
Plant acquisition | |||
| 2015-09-11 | Merck KGaA (Germany) Merck Serono (Germany) | construction of new premises |
Construction of new premises | |||
| 2015-09-10 | Takeda Pharmaceutical (Japan) Gencia (USA - VA) | mitochondrial agonists of the glucocorticoid receptor (MAGR) | R&D |
Hematologic diseases - Inflammatory diseases | R&D agreement | |
| 2015-09-10 | Curevac (Germany) | establishment of a new subsidiary in the US |
Establishment of a new subsidiary in the US | |||
| 2015-09-10 | Teva Pharmaceuticals (Israel) IBM Watson Health (USA - MA) | Watson Health Cloud | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-09-09 | Evotec (Germany) Pfizer (USA - NY) | fibrosis | collaboration |
Fibrotic diseases | Collaboration agreement | |
| 2015-09-09 | Visterra (USA - MA) Serum Institute of India (India) | VIS513 | dengue fever | licensing development manufacturing production commercialisation
|
Infectious diseases | Licensing agreement |
| 2015-09-09 | Opko Health (USA - Fl) The Scripps Research Institute (USA - CA) | lipoprotein signal peptidase (“Lsp”) inhibitors | infectious diseases | licensing |
Infectious diseases | Licensing agreement |
